Halozyme Therapeutics: Running Through 2027

Thomas Shields 352 Followers Follow Summary Halozyme Therapeutics shares have appreciated over 80% since my initial coverage and investment in 2024. My previous articles outlined a bullish investment thesis and detailed expectations for HALO's performance in the current year. HALO's stock performance has delivered significant returns, validating the earlier investment case and strategic positioning. I continue to monitor HALO's execution against my outlined expectations and the company's ability to sustain its growth trajectory. BlackJack3D/iStock via Getty Images Investment Thesis I've been following Halozyme Therapeutics, Inc. ( HALO ) since 2024 and it has provided significant alpha, outperforming the market by over 45% since May 2026 . HALO continues to deliver on their This article was written by Thomas Shields 352 Followers Follow I've been investing for almost 10 years with a focus on long term wealth creation through value growth investing, value investing, and dividend investing. I'm not a financial advisor or financial planner. I do not have a formal background in finance, I have a B.S. in Biology with a concentration in molecular cell biology. I am an avid reader, studier, and learner and have applied my rigorous undergraduate studies and research to investing. I plan to write articles on companies through the lens of fundamental value investing and attempt to find great companies at fair prices. All articles or comments are based on my personal experience, my own research, books/articles I've read, or general ideas about building long term wealth. Analyst’s Disclosure: I/we have a beneficial long position in the shares of HALO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I'm not an investment professional or investment advisor. This article is solely based on my own opinions and research. This is not meant to be a recommendation of the sale or the purchase of any securities. The investments or strategies discussed within this article are of my own personal opinions and commentary. This article has been written for educational and research purposes only. This article does not consider the reader’s financial situation, investment goals, needs, or any other personal circumstances. Investors should conduct their own research and perform their own due diligence before making any investment decisions. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.